Skip to content

Author

S. L. Pugh

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

Stereotactic Body Radiotherapy vs. Moderately Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer: A Randomized Clinical Trial

Importance The treatment of prostate cancer with radiotherapy is evolving. How quickly radiotherapy can be delivered, and the relative risks and benefits of such a treatment, is of significant public interest. Objective To determine whether stereotactic body radiotherapy (SBRT) was superior to moderately-hypofractionat...

R. J. Ellis, S. L. Pugh, James B. Yu et al. · 2 citations
Sep 2026

Safety and Biomarker Analysis of NRG-LU004: Phase I Trial of Accelerated or Conventionally Fractionated Radiotherapy Combined With Durvalumab in PD-L1 High Locally Advanced Non-Small Cell Lung Cancer

Background. Patients with advanced non-small cell lung cancer (NSCLC) and high PD-L1 (>50%) expression show improved outcomes with immune checkpoint inhibitors compared to chemotherapy. We hypothesized that concurrent durvalumab and radiotherapy (RT) without concurrent chemotherapy would be safe and feasible in patient...

Steven H. Lin, S. L. Pugh, D. D. Del Valle et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.